RNA testing uncovers 171 mutations driving MET exon 14 skipping in lung cancer

New probe has shown that RNA-based investigating tin amended the detection and mentation of clinically actionable genomic alterations that pb to MET exon 14 skipping successful patients with lung cancer—important biomarkers that whitethorn beryllium missed by DNA-only approaches. The findings from the survey published successful The Journal of Molecular Diagnostics are poised to amended diagnostic accuracy and assistance find patients' eligibility for MET-targeted therapies.